Journal Article

Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic

Nörz, Dominik, Kuballa, Lilith, Arend, Hannes, Brehm, Thomas T., Huber, Samuel, Lütgehetman, Marc, Schulze zur Wiesch, Julian, Kluwe, Johannes, Horvatits, Karoline, Wege, Henning, Horvatits, Thomas, Fründt, Thorben

2021

Overview

Patients with liver cirrhosis (LC) are considered to be at increased risk for mortality when acquiring SARS-CoV-2 infection and subsequently developing Corona Virus Disease 2019 (COVID-19). During the COVID-19 pandemic, hospitals are regarded as sites with increased risk of infection. Therefore, patient contacts are often limited to urgent indications, which could negatively affect disease monitoring. However, data regarding actual infection rates in cirrhotic patients is limited. The aim of this prospective study was to assess the incidence of COVID-19 in patients with LC with/without hepatocellular carcinoma (HCC) with physical presentation at our University Medical Center. Patients were enrolled between 1st April and 30th June 2020 at the University Medical Center Hamburg-Eppendorf, Germany. Symptoms of upper airway infection at baseline and presence of SARS-CoV-2 antibodies (IgG/IgM/IgA) were assessed at baseline and follow-up (FU) using an Electro-chemiluminescence immunoassay (Roche Elecsys). FU visits, including liver function test, clinical assessment and symptom questionnaire, were conducted after 6-8 weeks (FU-1) and 6 months (FU-2). Prior to inclusion of the first patient, obligatory face masks and personal distance were implemented as protective measures. A total of 150 patients were enrolled, 23% (n = 35) also had diagnosis of HCC (median age: 64 years, range: 19-86), 69% were male. Liver function according to Child-Pugh score (CPS) was: CPS A: 46% (n = 62); CPS B: 37% (n = 50); CPS C: 17% (n = 23). Clinical symptoms indicating upper airway infection were present in 53% (n = 77): shortness of breath (n = 40) and coughing (n = 28) were the most frequent. For the 150 patients enrolled, 284 outpatient visits were registered and 33 patients were admitted to the University Medical Center during the follow-up period. After a median of 52 days, n = 110 patients completed FU-1 and n = 72 completed FU-2 after a median of 6.1 months. Only in one patient, an 80-year-old man with stable liver function (CPS A) and advanced HCC, SARS-CoV-2 antibodies were detected at baseline and FU-1, while antibody testing was negative in the remaining patients at baseline, FU-1 and FU-2. The incidence of COVID-19 at our tertiary medical center during the pandemic was low in LC and HCC patients, when simple protective measures were implemented. Therefore, a routine care for patients with chronic liver diseases does not increase the risk of SARS-CoV-2 infection and should be maintained with protective measures.

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Adult / Aged / Aged, 80 and over / Antibodies / Biology and life sciences / Carcinoma, Hepatocellular - complications / Carcinoma, Hepatocellular - virology / Care and treatment / Chemiluminescence / Chronic infection / Cirrhosis / Cohort Studies / Corona / Coronaviruses / COVID-19 / COVID-19 - epidemiology / Diagnosis / Female / Germany - epidemiology / Health care facilities / Health risks / Hepatocellular carcinoma / Hepatoma / Humans / Immunoassay / Immunoglobulin A / Immunoglobulin G / Immunoglobulin M / Incidence / Liver / Liver cancer / Liver cirrhosis / Liver Cirrhosis - complications / Liver Cirrhosis - virology / Liver diseases / Liver Neoplasms - complications / Liver Neoplasms - virology / Male / Measurement / Medicine and health sciences / Medicine, Preventive / Methods / Middle Aged / Mortality / Mortality risk / Pandemics / Patients / Preventive health services / Prospective Studies / Respiratory tract / Risk / Risk factors / SARS-CoV-2 - pathogenicity / Severe acute respiratory syndrome / Severe acute respiratory syndrome coronavirus 2 / Signs and symptoms / Tertiary / Tertiary Care Centers - trends / Viral antibodies / Viral diseases / Viruses